Oncolytics Biotech is trading 5.51% lower at $0.47, with no verified catalyst identified for the decline. - Major U.S. indexes were higher, so the decline did not follow the broad market’s direction. - The latest identified developments were a REO 033 trial update and an ESMO presentation announcement, both reported before October 26; available sources do not link them to Monday’s move. - Trading volume and a clear company-specific or sector-wide explanation were not established.